Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.912 |
High Similarity |
NPD4908 |
Phase 1 |
0.8976 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.875 |
High Similarity |
NPD4625 |
Phase 3 |
0.871 |
High Similarity |
NPD1610 |
Phase 2 |
0.8537 |
High Similarity |
NPD1548 |
Phase 1 |
0.8462 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8425 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.8425 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8385 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8308 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8271 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8271 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8231 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.8168 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.812 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.803 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7966 |
Intermediate Similarity |
NPD846 |
Approved |
0.7966 |
Intermediate Similarity |
NPD940 |
Approved |
0.7951 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7902 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7883 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7881 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7872 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7868 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7863 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7863 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7852 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7846 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7842 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7842 |
Intermediate Similarity |
NPD6099 |
Approved |
0.784 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7832 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7832 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7829 |
Intermediate Similarity |
NPD4626 |
Approved |
0.782 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7805 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7801 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7786 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.777 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7746 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7737 |
Intermediate Similarity |
NPD1240 |
Approved |
0.773 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7717 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7712 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7708 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7708 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7687 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7655 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD37 |
Approved |
0.7647 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7642 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.7626 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7609 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.76 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7594 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7594 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7578 |
Intermediate Similarity |
NPD709 |
Approved |
0.7564 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.755 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7542 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7542 |
Intermediate Similarity |
NPD2860 |
Approved |
0.754 |
Intermediate Similarity |
NPD228 |
Approved |
0.7537 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7535 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7535 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7532 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.752 |
Intermediate Similarity |
NPD3022 |
Approved |
0.752 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7519 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7519 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7519 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7518 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7516 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD7466 |
Approved |
0.75 |
Intermediate Similarity |
NPD4965 |
Approved |
0.75 |
Intermediate Similarity |
NPD4966 |
Approved |
0.75 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7484 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7483 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7482 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7482 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD4339 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7481 |
Intermediate Similarity |
NPD1651 |
Approved |
0.748 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7465 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7463 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7463 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7458 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7458 |
Intermediate Similarity |
NPD2933 |
Approved |
0.745 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7436 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7429 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7429 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7417 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7415 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7413 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7407 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7405 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7391 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7386 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7361 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7358 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7357 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7353 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7353 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7351 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7347 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7344 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7343 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7343 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7338 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7338 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7338 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7313 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7313 |
Intermediate Similarity |
NPD3705 |
Approved |
0.731 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7302 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7293 |
Intermediate Similarity |
NPD2667 |
Approved |
0.7293 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7293 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7293 |
Intermediate Similarity |
NPD2668 |
Approved |
0.7292 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.728 |
Intermediate Similarity |
NPD968 |
Approved |
0.7278 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7278 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7259 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7254 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7254 |
Intermediate Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD844 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7244 |
Intermediate Similarity |
NPD6746 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7226 |
Intermediate Similarity |
NPD4055 |
Discovery |
0.7218 |
Intermediate Similarity |
NPD3443 |
Approved |
0.7218 |
Intermediate Similarity |
NPD3445 |
Approved |
0.7218 |
Intermediate Similarity |
NPD3444 |
Approved |
0.7218 |
Intermediate Similarity |
NPD4093 |
Discontinued |
0.7214 |
Intermediate Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.7214 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7211 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7209 |
Intermediate Similarity |
NPD7843 |
Approved |
0.72 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7195 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7195 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7192 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD288 |
Approved |
0.7188 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7185 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7185 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7185 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7172 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7172 |
Intermediate Similarity |
NPD5762 |
Approved |
0.717 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7167 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7164 |
Intermediate Similarity |
NPD4059 |
Approved |
0.7164 |
Intermediate Similarity |
NPD2286 |
Discontinued |
0.7164 |
Intermediate Similarity |
NPD3019 |
Approved |
0.7164 |
Intermediate Similarity |
NPD3095 |
Discontinued |
0.7162 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7161 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7154 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7154 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7153 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6581 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6580 |
Approved |
0.7133 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7121 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7115 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7113 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7111 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7105 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7103 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7103 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7103 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7103
|
Intermediate Similarity |
NPD5406 |
Approved |